huPBMC-NOG is a model for investigation of adult/mature cell populations.
This model permits the assessment of effector and memory T cells.
PBMC engrafted mice are optimally suited for studies immediately following engraftment as Graft vs. Host Disease (GvHD) limiting survival time to 4-6 weeks. In addition, the GvHD response can be used as a screening system for T cell modulating drugs, with readouts including body weight and clinical condition, liver injury and immune cell infiltration into organs.
Chart #1: Human CD45+ cells were enumerated by flow cytometry at daily intervals follow PBMC engraftment. Significant engraftment was observed after 14 days. The majority of human CD45+ cells are CD3+ T cells.
Chart #2:Irradiation exacerbates GvHD in PBMC engrafted NOG mice. Survival curves for PBMC engrafted NOG mice at increasing doses of radiation with, or without pre-treatment with anti-TNFa blocking antibody.